Digitalisierung in der Migränetherapie

Zusammenfassung

Digitalisierung ist ein viel verwendetes Schlagwort in der Medizin und hat auch die Migräne und ihre Therapie erreicht. Digitalisierung soll allerdings kein Selbstzweck sein, sondern die Behandlung von Patienten verbessern und die Arbeit von Behandlern erleichtern. Dieser Artikel beschäftigt sich mit den Bereichen der Migränemedizin, wo dies heute schon so ist bzw. zukünftig so sein kann.

Abstract

Digitalization is a commonly used keyword in medicine and also in the area of migraine and its therapy. However, digitalization should not be an end in itself, but should improve the treatment of patients and make the work of practitioners easier. This article summarizes the use of e-health applications for migraine medicine, today and in the future.

Schlüsselwörter

Migräne - Digitale Gesundheitsanwendung - Digitalisierung

Keywords

migraine - e-health application - digitalization

Publication History

Received: 27 December 2023

Accepted after revision: 22 April 2024

Article published online:
23 May 2024

• Literatur

• 1 Buse DC, Armand CE, Charleston L. et al. Barriers to care in episodic and chronic migraine: Results from the Chronic Migraine Epidemiology and Outcomes Study. Headache 2021; 61: 628-641
• 2 Katsuki M, Shimazu T, Kikui S. et al. Developing an artificial intelligence-based headache diagnostic model and its utility for non-specialists’ diagnostic accuracy. Cephalalgia Int J Headache 2023; 43: 3331024231156925
• 3 Göbel H, Frank B, Heinze A. et al. Gesundheitsverhalten von Migräne- und Kopfschmerzpatienten bei digitaler Therapiebegleitung mit der Migräne-App. Schmerz 2019; 33: 147-155
• 4 Raffaelli B, Mecklenburg J, Overeem LH. et al. Determining the Evolution of Headache Among Regular Users of a Daily Electronic Diary via a Smartphone App: Observational Study. JMIR MHealth UHealth 2021; 9: e26401
• 5 Jonker L, Fitzgerald L, Vanderpol J. et al. Digital diary App use for migraine in primary care: Prospective cohort study. Clin Neurol Neurosurg 2022; 216: 107225
• 6 Ramsey RR, Holbein CE, Powers SW. et al. A pilot investigation of a mobile phone application and progressive reminder system to improve adherence to daily prevention treatment in adolescents and young adults with migraine. Cephalalgia 2018; 38: 2035-2044
• 7 Tassorelli C, Jensen R, Allena M. et al. The added value of an electronic monitoring and alerting system in the management of medication-overuse headache: A controlled multicentre study. Cephalalgia 2017; 37: 1115-1125
• 8 Diener H-C, Donoghue S, Gaul C. et al. Prevention of medication overuse and medication overuse headache in patients with migraine: a randomized, controlled, parallel, allocation-blinded, multicenter, prospective trial using a mobile software application. Trials 2022; 23: 382
• 9 Oliveira Gonçalves AS, Laumeier I, Hofacker MD. et al. Study Design and Protocol of a Randomized Controlled Trial of the Efficacy of a Smartphone-Based Therapy of Migraine (SMARTGEM). Front Neurol 2022; 13: 912288
• 10 Bundesinstitut für Arztneimittel und Medizinprodukte. DiGA-Verzeichnis – M-Sense, Informationen für Fachkreise. Im Internet: https://diga.bfarm.de/de/verzeichnis/315/fachkreise ?; Stand: 18.03.2024
• 11 Casanova A, Vives-Mestres M, Donoghue S. et al. An observational study of self-reported migraine triggers and prospective evaluation of the relationships with occurrence of attacks enabled by a smartphone application (App). Headache 2022; 62: 1406-1415
• 12 Vo P, Paris N, Bilitou A. et al. Burden of Migraine in Europe Using Self-Reported Digital Diary Data from the Migraine Buddy© Application. Neurol Ther 2018; 7: 321-332
• 13 Goadsby PJ, Constantin L, Ebel-Bitoun C. et al. Multinational descriptive analysis of the real-world burden of headache using the Migraine Buddy application. Eur J Neurol 2021; 28: 4184-4193
• 14 Klan T, Diezemann-Prößdorf A, Guth A-L. et al. Attackenangst bei Migräne: Diagnostik und Behandlung. Schmerz 2023;
• 15 Gonzalez-Martinez A, Pagán J, Sanz-García A. et al. Machine-learning-based approach for predicting response to anti-calcitonin gene-related peptide (CGRP) receptor or ligand antibody treatment in patients with migraine: A multicenter Spanish study. Eur J Neurol 2022; 29: 3102-3111
• 16 Ruscheweyh R, Gossrau G, Dresler T. et al. Triptan non-response in specialized headache care: cross-sectional data from the DMKG Headache Registry. J Headache Pain 2023; 24: 135
• 17 Evcili G. Early and Long Period Follow-up Results of Low-Glycemic Index Diet for Migraine Prophylaxis. Ağrı – J Turk Soc Algol 2018;
• 18 Schröder T, Kühn G, Kordowski A. et al. A Digital Health Application Allowing a Personalized Low-Glycemic Nutrition for the Prophylaxis of Migraine: Proof-of-Concept Data from a Retrospective Cohort Study. J Clin Med 2022; 11: 1117
• 19 Bundesinstitut für Arzneimittel und Medizinprodukte. DiGA-Verzeichnis- sinCephalea – Migräneprophylaxe Information für Fachkreise. 2023; Im Internet: https://diga.bfarm.de/de/verzeichnis/01775/fachkreise Stand: 29.08.2023
• 20 Mit personalisierter Ernährung gegen Migräne – Moderne Migränetherapie mit sinCephalea Migräneprophylaxe. sinCephalea. Im Internet: https://sincephalea.de/wp-content/uploads/2023/08/090823_sC_Migraeneprophylaxe_digital.pdf Stand: 29.08.2023
• 21 Lelleck VV, Schulz F, Witt O. et al. A Digital Therapeutic Allowing a Personalized Low-Glycemic Nutrition for the Prophylaxis of Migraine: Real World Data from Two Prospective Studies. Nutrients 2022; 14: 2927
• 22 Schröder T, Brudermann HCB, Kühn G. et al. Efficacy of the Digital Therapeutic sinCephalea in the prophylaxis of migraine in patients with episodic migraine: study protocol for a digital, randomized, open-label, standard treatment controlled trial. Trials 2022; 23: 997
• 23 Universitätsklinikum Essen. Studienangebot der Klinik für Neurologie – 2022-01-Headacy. Im Internet: https://neurologie.uk-essen.de/studien/studienangebot/?studies_ume_id=11556 Stand: 20.03.2024